Amici include the Center for Reproductive Rights, ACLU-Reproductive Freedom Project, and Planned Parenthood Federation of America.
As a result of the District Court’s decision, people across the country may be denied access to mifepristone, even in states where abortion remains legal or protected. These individuals may suffer devastating personal, professional, educational, and health consequences as a result. Those impacts and burdens will fall hardest on communities most impacted by systemic racism and other forms of oppression and already facing barriers to care, including Black, Indigenous, and other people color, those with low incomes, LGBTQ+ people, young people, immigrants, people with disabilities, people living in rural areas, and those living at the intersection of these identities. Amici emphasize that the district court’s decision is contrary to the immense wealth of medical evidence demonstrating that medication abortion is one of the safest medication regimens in the United States and demonstrate that the “experts” the plaintiffs and the court rely on have been widely discredited in the medical and scientific community. Further, Judge Kacsmaryk’s decision exacerbates the current reproductive health care crisis in the wake of the Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization, which has left millions of people capable of pregnancy across the country without meaningful access to abortion, amplifying the need for access to mifepristone where such care is still available.
This brief was one of many filed in support of the FDA in Alliance for Hippocratic Medicine v. FDA. For more information on the case, click here.